Adagene Inc
978
Company Profile
Business description
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.
Contact
Xinghu Street, Suzhou Industrial Park
4th Floor, Building C14, No. 218
Jiangsu Province
Suzhou215123
CHNT: +86 51287773632
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
174
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,148.90 | 93.60 | 1.16% |
| CAC 40 | 8,078.10 | 93.37 | -1.14% |
| DAX 40 | 22,899.07 | 388.99 | -1.67% |
| Dow JONES (US) | 41,767.38 | 197.25 | -0.47% |
| FTSE 100 | 8,689.37 | 17.29 | -0.20% |
| HKSE | 24,219.95 | 551.19 | -2.23% |
| NASDAQ | 17,672.21 | 78.58 | -0.44% |
| Nikkei 225 | 37,751.88 | 93.54 | -0.25% |
| NZX 50 Index | 12,054.72 | 8.79 | 0.07% |
| S&P 500 | 5,650.88 | 24.41 | -0.43% |
| S&P/ASX 200 | 7,918.90 | 90.60 | 1.16% |
| SSE Composite Index | 3,408.95 | 17.48 | -0.51% |